Skip to main content
SpringerLink
Log in

Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis

  • Review Article
  • Published:
Chinese Journal of Cancer Research

Abstract

Metastatic breast cancer (MBC) is characterized by a combination of tumor growth, proliferation and metastatic progression and is typically managed with palliative intent. The benefit of standard systemic therapies is relatively limited and the disease is considered incurable suggesting the need to investigate the biological drivers of the various phases of the metastatic process in order to improve the selection of molecularly driven therapies. The detection, enumeration and molecular analysis of circulating tumor cells (CTCs) provide an intriguing opportunity to advance this knowledge. CTCs enumerated by the Food and Drugs Administration-cleared CellSearch™ system are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in MBC patients. Several published papers demonstrated the poor prognosis for MBC patients that presented basal CTC count ≥5 in 7.5 mL of blood. Therefore, the enumeration of CTCs during treatment for MBC provides a tool with the ability to predict progression of disease earlier than standard timing of anatomical assessment using conventional radiological tests. During the metastatic process cancer cells exhibit morphological and phenotypic plasticity undergoing epithelialmesenchymal transition (EMT). This important phenomenon is associated with down regulation of epithelial marker (e.g., EpCAM) with potential limitations in the applicability of current CTCs enrichment methods. Such observations translated in a number of investigations aimed at improving our capabilities to enumerate and perform molecular characterization of CTCs. Theoretically, the phenotypic analysis of CTCs can represent a “liquid” biopsy of breast tumor that is able to identify a new potential target against the metastatic disease and advance the development and monitoring of personalized therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2012. [Epub ahead of print].

    Google Scholar 

  2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.

    Article  PubMed  Google Scholar 

  4. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242–252.

    Article  PubMed  CAS  Google Scholar 

  5. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793–802.

    Article  PubMed  CAS  Google Scholar 

  6. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589–4594.

    Article  PubMed  CAS  Google Scholar 

  7. Gross HJ, Verwer B, Houck D, et al. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci U S A 1995;92:537–541.

    Article  PubMed  CAS  Google Scholar 

  8. Hawes D, Neville AM, Cote RJ. Occult metastasis. Biomed Pharmacother 2001;55:229–242.

    Article  PubMed  CAS  Google Scholar 

  9. Hu XC, Chow LW. Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res 2001;21:421–424.

    PubMed  CAS  Google Scholar 

  10. Witzig TE, Bossy B, Kimlinger T, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002;8:1085–1091.

    PubMed  Google Scholar 

  11. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002;25:104–110.

    Google Scholar 

  12. Terstappen LW, Rao C, Gross S, et al. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000;17:573–578.

    PubMed  CAS  Google Scholar 

  13. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–791.

    Article  PubMed  CAS  Google Scholar 

  14. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302–6309.

    Article  PubMed  Google Scholar 

  15. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213–3221.

    Article  PubMed  Google Scholar 

  16. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420–1430.

    Article  PubMed  Google Scholar 

  17. Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471–479.

    Article  PubMed  Google Scholar 

  18. Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008;19:891–897.

    Article  PubMed  Google Scholar 

  19. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153–5159.

    Article  PubMed  Google Scholar 

  20. Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010;17:199–204.

    Article  PubMed  Google Scholar 

  21. Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23:618–624.

    Article  PubMed  Google Scholar 

  22. Liu MC, Mego M, Nakamura S, et al. Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). J Clin Oncol 2011;29:abstr 10592.

  23. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.

    Article  PubMed  Google Scholar 

  24. Esserman LJ, Berry DA, Demichele A, et al. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242–3249.

    Article  PubMed  Google Scholar 

  25. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012;23:1144–1150.

    Article  PubMed  CAS  Google Scholar 

  26. Munzone E, Botteri E, Sandri MT, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2012;12:340–346.

    Article  PubMed  CAS  Google Scholar 

  27. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010;21:1765–1771.

    Article  PubMed  Google Scholar 

  28. Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012;104:1534–1541.

    Article  PubMed  Google Scholar 

  29. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? Cancer 2008;113:2422–2430.

    Article  PubMed  Google Scholar 

  30. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403–6409.

    Article  PubMed  CAS  Google Scholar 

  31. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009;27:3303–3311.

    Article  PubMed  Google Scholar 

  32. De Giorgi U, Mego M, Rohren EM, et al. 18F-FDG-PET/ CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010;51:1213–1218.

    Article  PubMed  Google Scholar 

  33. Mego M, De Giorgi U, Dawood S, et al. 18F-FDG PET/ CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. Int J Cancer 2011;129:417–423.

    Article  PubMed  CAS  Google Scholar 

  34. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.

    Article  PubMed  CAS  Google Scholar 

  35. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740–746.

    Article  PubMed  CAS  Google Scholar 

  36. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154:8–20.

    Article  CAS  Google Scholar 

  37. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–715.

    Article  PubMed  CAS  Google Scholar 

  38. Hollier BG, Evans K, Mani SA. The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009;14:29–43.

    Article  PubMed  Google Scholar 

  39. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927–939.

    Article  PubMed  CAS  Google Scholar 

  40. Tsuji T, Ibaragi S, Shima K, et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008;68:10377–10386.

    Article  PubMed  CAS  Google Scholar 

  41. Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-toepithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271–11278.

    Article  PubMed  CAS  Google Scholar 

  42. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.

    Article  PubMed  Google Scholar 

  43. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–791.

    Article  PubMed  CAS  Google Scholar 

  44. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235–1239.

    Article  PubMed  CAS  Google Scholar 

  45. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366–377.

    Article  PubMed  CAS  Google Scholar 

  46. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.

    Article  PubMed  Google Scholar 

  47. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392–18397.

    Article  PubMed  CAS  Google Scholar 

  48. Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970–3975.

    Article  PubMed  CAS  Google Scholar 

  49. Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010;102:561–569.

    Article  PubMed  CAS  Google Scholar 

  50. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.

    Article  PubMed  CAS  Google Scholar 

  51. Zieglschmid V, Hollmann C, Gutierrez B, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res 2005;25:1803–1810.

    PubMed  CAS  Google Scholar 

  52. Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005;42:155–196.

    Article  PubMed  CAS  Google Scholar 

  53. Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect? versus Veridex CellSearch? system. Int J Cancer 2012;130:1590–1597.

    Article  PubMed  CAS  Google Scholar 

  54. Aktas B, Müller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011;122:356–360.

    Article  PubMed  CAS  Google Scholar 

  55. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.

    Article  PubMed  CAS  Google Scholar 

  56. Rostagno P, Moll J, Bisconte J, et al. Detection of rare circulating breast cancer cells by filtration cytometry and identification by DNA content: sensitivity in an experimental model. Anticancer Res 1997;17:2481–2485.

    PubMed  CAS  Google Scholar 

  57. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156:57–63.

    Article  PubMed  CAS  Google Scholar 

  58. Pinzani P, Salvadori B, Simi L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006;37:711–718.

    Article  PubMed  CAS  Google Scholar 

  59. De Giorgi V, Pinzani P, Salvianti F, et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 2010;130:2440–2447.

    Article  PubMed  Google Scholar 

  60. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay? and the isolation by size of epithelial tumor cell method. Int J Cancer 2011;129:1651–1660.

    Article  PubMed  CAS  Google Scholar 

  61. Adams D, Makarova O, Zu P, et al. Isolation of Circulating Tumor Cells by Size Exclusion using Lithography Fabricated Precision Microfilters. Proceedings 102nd AACR meeting 2011, Orlando, FL, 2011:Abstr 2369.

    Google Scholar 

  62. Lin HK, Zheng S, Williams AJ, et al. Portable filterbased microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010;16:5011–5018.

    Article  PubMed  CAS  Google Scholar 

  63. Das CM, Becker F, Vernon S, et al. Dielectrophoretic segregation of different human cell types on microscope slides. Anal Chem 2005;77:2708–2719.

    Article  PubMed  CAS  Google Scholar 

  64. Medoro G, Gross S, Manaresi N, et al. Use of the DEPArray platform to detect, isolate, and molecularly characterize pure tumor cells from peripheral blood samples enriched using the CellSearch system. J Clin Oncol 2011;29:abstr 10616.

  65. Alpaugh KR, Bingham C, Fittipaldi P, et al. Mutational analysis of tissue and circulating tumor cells (CTCs) in advanced inflammatory breast cancer (IBC) reveals tumor heterogeneity. Implications for selection of molecular therapies? Cancer Res 2012;72(Suppl).

    Google Scholar 

  66. Cristofanilli M, De Gasperis G, Zhang L, et al. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clin Cancer Res 2002;8:615–619.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, P.R. China

    Xiaoshen Dong

  2. Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA

    Xiaoshen Dong, R. Katherine Alpaugh & Massimo Cristofanilli

  3. Department of Medical Oncology, G. Morris Dorrance Jr. Endowed Chair in Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room P3043, Philadelphia, PA, 19111-2497, USA

    Massimo Cristofanilli

Authors
  1. Xiaoshen Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Katherine Alpaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Cristofanilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Cristofanilli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dong, X., Alpaugh, R.K. & Cristofanilli, M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin. J. Cancer Res. 24, 388–398 (2012). https://doi.org/10.1007/s11670-012-0279-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-012-0279-4

Key Words

Search

Navigation